All In MedTech

Device Trial Radar · NCT05215587

Scandinavian Trial of Uncomplicated Aortic Dissection Therapy

Last checked: Nov 20, 2026Latest source record: Aug 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 554 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

554

Planned (sponsor's estimate)

Start

May 24, 2023

Primary completion

Dec 31, 2026

Study completion Dec 31, 2030

Sponsor

Lead sponsor
University of AarhusAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Swedish Research Council; Swedish Heart Lung Foundation
First posted
Jan 31, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The introduction of thoracic endovascular aortic repair (TEVAR) in 1994 has radically changed the treatment of thoracic aortic pathology, and TEVAR is now the recommended therapy for "complicated" TBADs and other thoracic aorta diseases. To date, the use of TEVAR in the treatment of "uncomplicated" dissections (uTBAD) is uncertain, although it is presumed that a prophylactic procedure can prevent later complex surgery and early death. Several analyses have found that TEVAR confers improved aortic remodeling and possibly survival, although these were underpowered for this specific outcome. In addition, there are several reports regarding the uncertain benefit or harm of this intervention in the vascular surgery community. Put another way, there is equipoise, and the need for robust evidence in the form of a randomized clinical trial has been clearly iterated by the European Society of Vascular Surgery. This randomized, open-label, two-armed controlled study directly addresses this question of whether TEVAR alters 5-year survival among patients with an uTBAD. Patients will be randomized to either standard medical therapy (SMT) alone or TEVAR in addition to SMT. The primary outcome is 5-year survival, while secondary outcomes include aortic-related mortality, neurological events, quality of life, costs, re interventions and readmissions. in addition, subgroup analyses based on the extent of treatment. Sample size calculations based on previous reports indicate the need to include approximately 554 patients. Patients will be recruited from multiple centres in Scandinavia. Based on the population (24 million) and incidence of uTBAD (approximately 480 per year), and depending on the total number of participating centres, a conservative estimate of two to three years is required for enrolment.

Conditions

  • Aortic Dissection

Interventions

  • TEVARDevice

    A TEVAR stent graft will be placed in the descending aorta in order to cover the primary entry of the dissection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SurvivalTime frame: Five years

Locations

28 sites in 6 countries. Site status is shown where the registry gives one.

  • Aalborg University Hospital

    Aalborg, Denmark · Recruiting

  • Aarhus University Hospital

    Aarhus, Denmark · Recruiting

  • Copenhagen University Hospital, Rigshospital

    Copenhagen, Denmark · Recruiting

25 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.